Replies to post #57493 on Ariad Pharmaceuticals Inc fka ARIA

[investor maven]

Of course he did... after the FDA's action.
And he also continues to support ponatinib use and clinical studies to identify its usefulness in less heavily pretreated populations. Meaning first and second line use. I guess he is still a strong ponatinib booster because of his concerns...